NeuroBo Pharmaceuticals Inc (NRBO) News

Form 8-K - Current report

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 8-K - Current report

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire CAMBRIDGE, Mass., Sept. 3, 2024 CAMBRIDGE...

Form DEF 14A - Other definitive proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update PR Newswire CAMBRIDGE, Mass., Aug. 14, 2024...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report